Search Results

Biotheryx, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for BTX-9341, a novel cyclin-dependent kinase 4/6 (CDK4/6) bifunctional degrader.

Biotheryx, Inc. announced it has entered into a Research Collaboration and License agreement with Incyte to discover and develop targeted protein degraders for novel oncology targets.

Biotheryx, Inc. announced two poster presentations at the 2023 American Society of Clinical Oncology Annual Meeting, being held June 2–6, 2023, in Chicago, Illinois and online.

Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) in areas of high unmet medical need, today announced that members of its senior management team will participate in two panel discussions at the Wells Fargo 2023 Targeted Protein Degradation Virtual Summit.

Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced data presentations on two first-in-class programs at the American Association for Cancer Research (AACR) 2023 Annual Meeting held in Orlando, Florida, on April 14–19, 2023.

Biotheryx, Inc. today announced the appointment of Tracy Lawhon, J.D., as Chief Development Officer (CDO).

Biotheryx, Inc. today announced that it will present preclinical data from its targeted protein degrader programs at the 5th Annual Targeted Protein Degradation Summit, being held October 25-28, 2022, in Boston, Massachusetts.

Biotheryx, Inc. today announced the appointment of Jeff Caravella as Chief Financial Officer.

BioTheryX, Inc. today announced that Nancy Miller-Rich has assumed the role of Chair of the BioTheryX Board of Directors.

BioTheryX, Inc. today announced the appointment of Sahm Nasseri as Chief Business Officer.